Beyond gold: the chemoenhancing mechanism and therapeutic potential of auranofin in melanoma

Objective: The objective of the current study was to evaluate the chemosensitizing capacity of auranofin (AF), a gold (I) complex traditionally used in rheumatoid arthritis treatment, in potentiating the cytotoxic effects of doxorubicin (DOX) in melanoma cell models, specifically drug-sensitive (B16...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaofeng Wang, Yingnan Liu, Wuqiong Zhang, Zhongda Li, Su Li, Jiaxin Chen, Qi Li, Xiaoman Suo, Yanqiao Zeng, Guofang Zhang, Yang Li
Format: Article
Language:English
Published: China Anti-Cancer Association 2025-06-01
Series:Cancer Biology & Medicine
Subjects:
Online Access:https://www.cancerbiomed.org/content/22/6/672
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849428313040224256
author Xiaofeng Wang
Yingnan Liu
Wuqiong Zhang
Zhongda Li
Su Li
Jiaxin Chen
Qi Li
Xiaoman Suo
Yanqiao Zeng
Guofang Zhang
Yang Li
author_facet Xiaofeng Wang
Yingnan Liu
Wuqiong Zhang
Zhongda Li
Su Li
Jiaxin Chen
Qi Li
Xiaoman Suo
Yanqiao Zeng
Guofang Zhang
Yang Li
author_sort Xiaofeng Wang
collection DOAJ
description Objective: The objective of the current study was to evaluate the chemosensitizing capacity of auranofin (AF), a gold (I) complex traditionally used in rheumatoid arthritis treatment, in potentiating the cytotoxic effects of doxorubicin (DOX) in melanoma cell models, specifically drug-sensitive (B16F10) and multidrug-resistant (B16F10/ADR) variants. Methods: Experimental measurements, including in vitro cytotoxicity and apoptosis assays, surface plasmon resonance (SPR), immunoblotting assays, as well as theoretical calculations, such as molecular docking and molecular dynamics (MD) simulations, were used to systematically delineate the interaction dynamics between AF and thioredoxin reductase 1 (TrxR1). The anti-tumor efficacy of co-treatment with AF and DOX was assessed by examining cell viability and apoptotic rates. Results: Co-treatment with AF and DOX significantly increased anti-tumor efficacy, as evidenced by reduced cell viability and increased apoptotic rates. This synergistic effect was attributed to inhibition of TrxR1 by AF, which compromised tumor cell antioxidant defenses and elevated intracellular reactive oxygen species (ROS), thereby enhancing apoptotic pathways. Notably, AF treatment mitigated the heightened TrxR activity in DOX-resistant cells, intensifying the pro-oxidant effects of DOX, leading to increased ROS production and cell death. The data also showed that AF binds with high affinity to the selenocysteine residue within the catalytic site of TrxR1, which partially overlapped with the binding site of the endogenous substrate, thioredoxin (Trx), but with greater avidity. This unique binding configuration impedes the reduction of Trx by TrxR1, triggering an apoptotic response in cancer cells. Conclusions: This study underscores the chemosensitizing potential of AF in overcoming multidrug resistance in cancer therapy through redox modulation. The molecular mechanism of action underlying AF on TrxR1 demonstrated the unique binding configuration that impedes the reduction of Trx by TrxR1 and instigates an apoptotic response in cancer cells. These findings pave the way for the clinical application of AF as a chemosensitizer, offering a novel approach to augment the efficacy of existing chemotherapy regimens.
format Article
id doaj-art-d48ea3504d0c48879bba991ea1c55d76
institution Kabale University
issn 2095-3941
language English
publishDate 2025-06-01
publisher China Anti-Cancer Association
record_format Article
series Cancer Biology & Medicine
spelling doaj-art-d48ea3504d0c48879bba991ea1c55d762025-08-20T03:28:43ZengChina Anti-Cancer AssociationCancer Biology & Medicine2095-39412025-06-0122667268910.20892/j.issn.2095-3941.2025.0026Beyond gold: the chemoenhancing mechanism and therapeutic potential of auranofin in melanomaXiaofeng Wang0Yingnan Liu1Wuqiong Zhang2Zhongda Li3Su Li4Jiaxin Chen5Qi Li6Xiaoman Suo7Yanqiao Zeng8Guofang Zhang9Yang Li10Laboratory of Inflammation and Vaccines, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518005, ChinaLaboratory of Inflammation and Vaccines, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518005, ChinaLaboratory of Inflammation and Vaccines, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518005, ChinaLaboratory of Inflammation and Vaccines, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518005, ChinaLaboratory of Inflammation and Vaccines, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518005, ChinaLaboratory of Inflammation and Vaccines, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518005, ChinaLaboratory of Inflammation and Vaccines, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518005, ChinaLaboratory of Inflammation and Vaccines, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518005, ChinaLaboratory of Inflammation and Vaccines, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518005, ChinaLaboratory of Inflammation and Vaccines, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518005, ChinaLaboratory of Inflammation and Vaccines, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518005, ChinaObjective: The objective of the current study was to evaluate the chemosensitizing capacity of auranofin (AF), a gold (I) complex traditionally used in rheumatoid arthritis treatment, in potentiating the cytotoxic effects of doxorubicin (DOX) in melanoma cell models, specifically drug-sensitive (B16F10) and multidrug-resistant (B16F10/ADR) variants. Methods: Experimental measurements, including in vitro cytotoxicity and apoptosis assays, surface plasmon resonance (SPR), immunoblotting assays, as well as theoretical calculations, such as molecular docking and molecular dynamics (MD) simulations, were used to systematically delineate the interaction dynamics between AF and thioredoxin reductase 1 (TrxR1). The anti-tumor efficacy of co-treatment with AF and DOX was assessed by examining cell viability and apoptotic rates. Results: Co-treatment with AF and DOX significantly increased anti-tumor efficacy, as evidenced by reduced cell viability and increased apoptotic rates. This synergistic effect was attributed to inhibition of TrxR1 by AF, which compromised tumor cell antioxidant defenses and elevated intracellular reactive oxygen species (ROS), thereby enhancing apoptotic pathways. Notably, AF treatment mitigated the heightened TrxR activity in DOX-resistant cells, intensifying the pro-oxidant effects of DOX, leading to increased ROS production and cell death. The data also showed that AF binds with high affinity to the selenocysteine residue within the catalytic site of TrxR1, which partially overlapped with the binding site of the endogenous substrate, thioredoxin (Trx), but with greater avidity. This unique binding configuration impedes the reduction of Trx by TrxR1, triggering an apoptotic response in cancer cells. Conclusions: This study underscores the chemosensitizing potential of AF in overcoming multidrug resistance in cancer therapy through redox modulation. The molecular mechanism of action underlying AF on TrxR1 demonstrated the unique binding configuration that impedes the reduction of Trx by TrxR1 and instigates an apoptotic response in cancer cells. These findings pave the way for the clinical application of AF as a chemosensitizer, offering a novel approach to augment the efficacy of existing chemotherapy regimens.https://www.cancerbiomed.org/content/22/6/672auranofintrxr1anti-cancerdrug resistancemolecular dynamics simulation
spellingShingle Xiaofeng Wang
Yingnan Liu
Wuqiong Zhang
Zhongda Li
Su Li
Jiaxin Chen
Qi Li
Xiaoman Suo
Yanqiao Zeng
Guofang Zhang
Yang Li
Beyond gold: the chemoenhancing mechanism and therapeutic potential of auranofin in melanoma
Cancer Biology & Medicine
auranofin
trxr1
anti-cancer
drug resistance
molecular dynamics simulation
title Beyond gold: the chemoenhancing mechanism and therapeutic potential of auranofin in melanoma
title_full Beyond gold: the chemoenhancing mechanism and therapeutic potential of auranofin in melanoma
title_fullStr Beyond gold: the chemoenhancing mechanism and therapeutic potential of auranofin in melanoma
title_full_unstemmed Beyond gold: the chemoenhancing mechanism and therapeutic potential of auranofin in melanoma
title_short Beyond gold: the chemoenhancing mechanism and therapeutic potential of auranofin in melanoma
title_sort beyond gold the chemoenhancing mechanism and therapeutic potential of auranofin in melanoma
topic auranofin
trxr1
anti-cancer
drug resistance
molecular dynamics simulation
url https://www.cancerbiomed.org/content/22/6/672
work_keys_str_mv AT xiaofengwang beyondgoldthechemoenhancingmechanismandtherapeuticpotentialofauranofininmelanoma
AT yingnanliu beyondgoldthechemoenhancingmechanismandtherapeuticpotentialofauranofininmelanoma
AT wuqiongzhang beyondgoldthechemoenhancingmechanismandtherapeuticpotentialofauranofininmelanoma
AT zhongdali beyondgoldthechemoenhancingmechanismandtherapeuticpotentialofauranofininmelanoma
AT suli beyondgoldthechemoenhancingmechanismandtherapeuticpotentialofauranofininmelanoma
AT jiaxinchen beyondgoldthechemoenhancingmechanismandtherapeuticpotentialofauranofininmelanoma
AT qili beyondgoldthechemoenhancingmechanismandtherapeuticpotentialofauranofininmelanoma
AT xiaomansuo beyondgoldthechemoenhancingmechanismandtherapeuticpotentialofauranofininmelanoma
AT yanqiaozeng beyondgoldthechemoenhancingmechanismandtherapeuticpotentialofauranofininmelanoma
AT guofangzhang beyondgoldthechemoenhancingmechanismandtherapeuticpotentialofauranofininmelanoma
AT yangli beyondgoldthechemoenhancingmechanismandtherapeuticpotentialofauranofininmelanoma